Calvin Sandra's Form 4 filing
Travere Therapeutics, Inc. (TVTX) · filed May 12, 2022
- Accession no.
- 0001209191-22-028706
- Filed
- May 12, 2022
- Trade date
- May 10-11, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $19.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Calvin SandraCIK 0001882909 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 10, 2022 | Common Stock | SSaleDisposed | −436 | $21.51 | −$9,378.36 | 36,178 | Direct | |
| May 11, 2022 | Common Stock | SSaleDisposed | −445 | $21.92 | −$9,754.4 | 35,733 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.